Table 6. Correlation of the expression of MT and ERCC1 with the drug response pattern using HDRA and the clinicopathological data of CCA patients.

Variables	N (33)	MT			ERCC1
		Low	High	p	Low	High	p
20 μg/ml cisplatin
Non-response	24	10	14	0.118	9	15	0.057
Response	9	7	2		7	2
25 μg/ml cisplatin
Resistance	15	4	11	0.015*	4	11	0.037*
Sensitive	18	13	5		12	6
Sex
Male	22	12	10	0.721	12	10	0.465
Female	11	5	6		4	7
Age (year)
Less than 63	15	8	7	1.000	6	9	0.491
63 or greater	18	9	9		10	8
Tumor site
Intrahepatic	22	11	11	1.000	11	11	1.000
Extrahepatic	11	5	6		6	5
Histology
Papillary	10	7	3	0.259	5	5	1.000
Non-papillary	23	10	13		11	12
Marginal status
Free margin	18	12	6	0.150	11	7	0.209
Not free margin	11	4	7		8	3
Not applicable	4	1	3		2	2
Primary tumor (T)
Is, I, II	13	8	5	0.642	8	5	0.236
III, IV	18	8	10		8	10
Not applicable	2	1	1		0	2
Reginal lymph node (N) metastasis
No	15	7	8	0.879	7	8	0.879
Yes	9	5	4		5	4
Not applicable	9	5	4		4	5
Distance metastasis (M)
No	15	6	9	0.481	8	7	0.384
Yes	5	3	2		1	4
Not applicable	13	8	5		7	6
TNM stage
I,II	9	7	2	0.089	5	4	0.570
III,IV	23	9	14		11	12
Stage unknown	1	1	0		0	1

*P<0.005, statistically significant